keyword
MENU ▼
Read by QxMD icon Read
search

Psa

keyword
https://www.readbyqxmd.com/read/29346783/does-2-pro-prostate-specific-antigen-meet-the-criteria-to-justify-its-inclusion-in-the-clinical-decision-making-process
#1
Angeles Sanchis-Bonet, Marta Barrionuevo-González, Ana Bajo-Chueca, Nelson Morales-Palacios, Manuel Sanchez-Chapado
INTRODUCTION: To assess whether [-2]pro-prostate-specific antigen (p2PSA) meets the criteria to justify its inclusion in a predictive model of prostate cancer (PCa) diagnosis and in the clinical decision-making process. MATERIALS AND METHODS: A total 172 men with total prostate-specific antigen of 2-10 ng/mL underwent measurement of free PSA and p2PSA before prostate biopsy in an observational and prospective study. From these measurements, the Prostate Health Index (PHI) was calculated...
January 18, 2018: Urologia Internationalis
https://www.readbyqxmd.com/read/29345442/lung-uptake-of-fluorine-18-fluoroethyl-choline-pet-ct-in-patients-with-prostate-cancer
#2
Daniele A Pizzuto, Salvatore Annunziata, Francesco P Ieria, Carmelo Caldarella, Maria A Isgrò, Valerio Lanni, Gaia Bencivenga, Vittoria Rufini, Alessandro Giordano
BACKGROUND: Metastatic spreading to the lungs is a negative prognostic factor in patients with prostate cancer (PC). Aim of our study was to assess the prevalence of lung PC metastases in patients with fluorine-18 fluoroethyl-choline (F-18-FECh) PET-CT positive lung lesions and the role of Gleason Score (GS) and common biochemical markers in predicting metastatic spreading to the lungs. METHODS: We retrospectively evaluated the scans of 1283 patients ongoing (F-18-FECh) PET-CT for PC between May 2010 and July 2014...
January 17, 2018: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29344794/ticagrelor-for-secondary-prevention-of-atherothrombotic-events-after-myocardial-infarction-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#3
REVIEW
Xavier G L V Pouwels, Robert Wolff, Bram L T Ramaekers, Anoukh Van Giessen, Shona Lang, Steve Ryder, Gill Worthy, Steven Duffy, Nigel Armstrong, Jos Kleijnen, Manuela A Joore
The National Institute for Health and Care Excellence (NICE) invited AstraZeneca, the manufacturer of ticagrelor (Brilique®), to submit evidence on the clinical and cost effectiveness of ticagrelor 60 mg twice daily (BID) in combination with low-dose aspirin [acetylsalicylic acid (ASA)] compared with ASA only for secondary prevention of atherothrombotic events in patients with a history of myocardial infarction (MI) and who are at increased risk of atherothrombotic events. Kleijnen Systematic Reviews Ltd (KSR), in collaboration with Maastricht University Medical Centre+, was commissioned as the evidence review group (ERG)...
January 18, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29344303/erratum-improvement-of-prostate-cancer-diagnosis-by-detecting-psa-glycosylation-specific-changes-erratum
#4
Esther Llop, Montserrat Ferrer-Batallé, Sílvia Barrabés, Pedro Enrique Guerrero, Manel Ramírez, Radka Saldova, Pauline M Rudd, Rosa N Aleixandre, Josep Comet, Rafael de Llorens, Rosa Peracaula
[This corrects the article DOI: 10.7150/thno.15226.].
2018: Theranostics
https://www.readbyqxmd.com/read/29344092/engaging-the-primary-care-community-to-encourage-appropriate-prostate-cancer-screening
#5
Malhar P Patel, Ariel Schulman, Kevin P Shah, John B Anderson, Thomas J Polascik
Prostate-specific antigen (PSA) screening for prostate cancer remains a controversial topic, particularly in the primary care community. Our multidisciplinary prostate screening panel at Duke University Health System, USA created a nuanced PSA screening algorithm, implemented it into the Electronic Health Record of Duke Primary Care, and conducted outreach meetings with primary care practices to support its rollout. Through this project, we identified areas of concern among primary care clinicians regarding PSA screening that we structured into two major categories: ideological opposition and logistical opposition...
January 2018: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/29343507/early-and-sustained-efficacy-with-apremilast-monotherapy-in-biological-na%C3%A3-ve-patients-with-psoriatic-arthritis-a-phase-iiib-randomised-controlled-trial-active
#6
Peter Nash, Kamal Ohson, Jessica Walsh, Nikolay Delev, Dianne Nguyen, Lichen Teng, Juan J Gómez-Reino, Jacob A Aelion
OBJECTIVE: Evaluate apremilast efficacy across various psoriatic arthritis (PsA) manifestations beginning at week 2 in biological-naïve patients with PsA. METHODS: Patients were randomised (1:1) to apremilast 30 mg twice daily or placebo. At week 16, patients whose swollen and tender joint counts had not improved by ≥10% were eligible for early escape. At week 24, all patients received apremilast through week 52. RESULTS: Among 219 randomised patients (apremilast: n=110; placebo: n=109), a significantly greater American College of Rheumatology 20 response at week 16 (primary outcome) was observed with apremilast versus placebo (38...
January 17, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29343039/-development-of-a-chinese-nomogram-based-on-muti-parametric-magnetic-resonance-for-predicting-the-probability-of-prostate-cancer-in-patients-after-initial-negative-biopsy
#7
C Huang, G J Ji, G Song, H Wang, Y K Chen, L Q Zhou
Objective: To develop a predictive nomogram based on multi-parametric magnetic resonance imaging (mpMRI) information to identify men more likely to have a cancer diagnosed on repeat prostate biopsy. Methods: The clinical data of 237 patients who received repeat prostate biopsy after initial negative biopsy from Department of Urology of Peking University First Hospital between January 2001 and August 2016 was reviewed. Patient age, body mass index (BMI), serum total prostate-specific antigen (PSA), percent free PSA (f/t), prostate volume (PV), PSA density (PSAD), PSA velocity (PSAV), digital rectal examination (DRE), transrectal ultrasound (TRUS)and mpMRI results were included in the univariate and multivariate analysis...
January 9, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/29342473/effectiveness-of-early-adalimumab-therapy-in-psoriatic-arthritis-patients-from-reuma-pt-early-psa
#8
Helena Santos, Mónica Eusébio, Joana Borges, Diana Gonçalves, Pedro Ávila-Ribeiro, Daniela Santos Faria, Carina Lopes, João Rovisco, Ana Águeda, Patrícia Nero, Paula Valente, Ana Rita Cravo, Maria José Santos
Objective To compare outcomes in psoriatic arthritis (PsA) patients initiating adalimumab (ADA), with short- and long-term disease duration and to evaluate the potential effect of concomitant conventional synthetic disease-modifying antirheumatic drugs (csDMARD) or glucocorticoids. Methods Analyses included adult PsA patients registered in the Rheumatic Diseases Portuguese Register (Reuma.pt) between June 2008-June 2016 who received ADA for ≥3 months. Psoriatic Arthritis Response Criteria (PsARC) response, tender and swollen joint count, inflammatory parameters, patient (PtGA) and physician global assessment (PhGA), Disease Activity Score-28 joints (DAS28), and Health Assessment Questionnaire Disability Index (HAQ-DI) were compared between patients with <5 years of disease (early PsA) and those with ≥5 years of disease duration (late PsA)...
October 2017: Acta Reumatológica Portuguesa
https://www.readbyqxmd.com/read/29341501/tadalafil-improves-symptoms-erectile-function-and-quality-of-life-in-patients-with-lower-urinary-tract-symptoms-suggestive-of-benign-prostatic-hyperplasia-kyu-pro-study
#9
Ryosuke Takahashi, Minoru Miyazato, Hisae Nishii, Yasuhiro Sumino, Kazuo Takayama, Masako Onzuka, Takuma Oshiro, Seiichi Saito, Naohiro Fujimoto, Hiromitsu Mimata, Masatoshi Eto
OBJECTIVES: Effect of tadalafil on lower urinary tract symptoms (LUTS), erectile function and quality of life (QoL) were prospectively evaluated in patients with benign prostatic hyperplasia (BPH) at multicenter. METHODS: Eligible men were ≥40 years who had no treatment with alpha-blocker for BPH, with total International Prostate Symptom Score (IPSS) ≥8, IPSS-QOL ≥2 and prostate volume ≥20 mL. Data were collected on age, body mass index (BMI), and prostate specific antigen (PSA)...
January 2018: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/29341453/mechanism-underlying-the-negative-effect-of-prostate-volume-on-the-outcome-of-extensive-transperineal-ultrasound-guided-template-prostate-biopsy
#10
Takayoshi Demura, Takenori Takada, Naohiko Shimoda, Takaya Hioka, Yoshihumi Iwaguchi, Shin Ichihara, Hiroko Gotoda
Previous studies have indicated a possible relationship between increased prostate volume (PV) and decreased biopsy yield, although the mechanism involved is unclear. We evaluated 1650 patients who underwent template biopsy. The distribution of 993 cancer lesions in 302 prostatectomy specimens was compared with the biopsy data to determine whether each lesion was detected. A receiver operating characteristic (ROC) model was used to determine the diagnostic accuracy of prostate-specific antigen (PSA) and related markers...
January 17, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29341216/primary-scarring-alopecia-a-retrospective-study-of-89-patients-in-taiwan
#11
Hsing-Jou Su, An-Yu Cheng, Cheng-Han Liu, Chia-Bau Chu, Chaw-Ning Lee, Chao-Kai Hsu, Julia Yu-Yun Lee, Chao-Chun Yang
Primary scarring alopecia (PSA) is caused by irreversible damage to the hair epithelial stem cells that reside in hair follicles. There is limited published work regarding PSA amongst the Asian population. The aim of this study was to evaluate the clinical features and to characterize the subtypes of PSA in southern Taiwan. In this retrospective case series, we reviewed 89 patients with pathology-confirmed PSA. The data was collected from National Cheng Kung University Hospital between 1988 through 2016. The clinical and histological data were reviewed, and the patients were characterized into different subtypes of PSA based on the clinical features and histological findings...
January 16, 2018: Journal of Dermatology
https://www.readbyqxmd.com/read/29340038/diagnostic-performance-of-68gallium-psma-11-pet-ct-to-detect-significant-prostate-cancer-and-comparison-with-18fec-pet-ct
#12
Manuela A Hoffmann, Matthias Miederer, Helmut J Wieler, Christian Ruf, Frank M Jakobs, Mathias Schreckenberger
Background: Radiolabeled prostate-specific membrane antigen (PSMA) has proven to be a highly accurate method to detect recurrence and metastases of prostate cancer, but only sparse data is available about its performance in the diagnosis of clinically significant primary prostate cancer. Methods: We compared 68Ga-PSMA-11 PET/CT in 25 patients with 18FEC PET/CT in 40 patients with suspected prostate carcinoma based on an increased PSA level.The PET/CT results were compared with the histopathologic Gleason Score (GS) of biopsies...
December 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29340015/apatinib-alone-or-combined-with-radiotherapy-in-metastatic-prostate-cancer-results-from-a-pilot-multicenter-study
#13
Feng Zhao, Wei Tian, Ming Zeng, Jianling Xia, Honglin Hu, Xinbao Hao, Liangfu Han, Hao Liu, Yangke He, Xueqiang Zhu, Liang Liang, Rui Ao, Min Wei, Lili Deng, Yuquan Wei
Background: To study safety and efficacy of apatinib in combination of radiotherapy in patients with symptomatic bony disease prostate cancer(SBPC), based on the potential synergistic antitumor activity between apatinib and Radiation Therapy (RT). Patients and methods: In phase I dose escalation part, 18 patients received apatinib dose at 250 mg every other day, 250 mg daily and 500 mg daily. In phase II part, the 250 mg daily cohorts were expanded to 20 patients in combination of RT (6 Gy/fraction, 5 fraction in total), one patient lost followed up and excluded the study, comparing with RT alone cohort with 10 patients, ratio of RT to RT + apatinib was 1 to 2...
December 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29339807/overexpression-of-%C3%AE-1-6-fucosyltransferase-in-the-development-of-castration-resistant-prostate-cancer-cells
#14
Naseruddin Höti, Shuang Yang, Yingwei Hu, Punit Shah, Michael C Haffner, Hui Zhang
Glycosylation is recognized as one of the most common modifications on proteins. Recent studies have shown that aberrant expression of α (1,6) fucosyltransferase (FUT8), which catalyzes the transfer of fucose from GDP-fucose to core-GlcNAc of the N-linked glycoproteins, modulates cellular behavior that could lead to the development of aggressive prostate cancer. While the relationship between the abnormal expression of FUT8 and glycoprotein fucosylation in different prostate cancer cells has been demonstrated, there is no evidence that shows dysregulated fucosylation might be involved in prostate cancer progression from androgen-dependent to castration-resistant prostate cancer...
January 16, 2018: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/29339806/tumor-characteristics-treatments-and-oncological-outcomes-of-prostate-cancer-in-men-aged-%C3%A2-50-years-a-population-based-study
#15
Raisa S Pompe, Ariane Smith, Marco Bandini, Michele Marchioni, Tristan Martel, Felix Preisser, Sami-Ramzi Leyh-Bannurah, Jonas Schiffmann, Fred Saad, Hartwig Huland, Markus Graefen, Shahrokh F Shariat, Derya Tilki, Pierre I Karakiewicz
BACKGROUND: To examine clinical characteristics, treatment modalities and oncological outcomes of prostate cancer (PCa) according to young (≤50) vs. old age. METHODS: Of 407,599 men with primary adenocarcinoma of the prostate within the Surveillance, Epidemiology and End Results (SEER)-database (2004 to 2013), 18,387 were aged ≤50 years (4.5%). Time trends, cumulative incidence, and competing risks regression (CRR) analyses tested for differences between young and old patients...
January 16, 2018: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/29339080/prostate-cancer-disseminated-tumor-cells-are-rarely-detected-in-the-bone-marrow-of-localized-patients-undergoing-radical-prostatectomy-across-multiple-rare-cell-detection-platforms
#16
Heather J Chalfin, Stephanie A Glavaris, Paymaneh D Malihi, Jamie M Sperger, Michael A Gorin, Changxue Lu, C Rory Goodwin, Yan Chen, Emily A Caruso, Ruth Dumpit, Peter Kuhn, Joshua M Lang, Peter S Nelson, Jun Luo, Kenneth J Pienta
PURPOSE: Prostate circulating tumor cells escape into the peripheral blood and enter the bone marrow as disseminated tumor cells, representing an early step before conventionally detectable metastasis. It is unclear how frequently this occurs in localized disease, and existing detection methods rely on epithelial markers with low specificity and sensitivity. Here we employed multiple methodologies of disseminated tumor cell detection in bone marrow harvested at radical prostatectomy. MATERIALS AND METHODS: Bone marrow was harvested from 208 clinically localized patients, 16 controls, and 5 metastatic patients, with peripheral blood from 37 metastatic patients...
January 12, 2018: Journal of Urology
https://www.readbyqxmd.com/read/29338305/safety-and-feasibility-of-prostate-stereotactic-ablative-radiotherapy-using-multi-modality-imaging-and-flattening-filter-free
#17
Aileen Duffton, Azmat Sadozye, Lynsey Devlin, Nicholas MacLeod, Carolynn Lamb, Suzanne Smith, Philip McLoone, Muthu Sankaralingam, John Foster, Stephanie Paterson, Stefanie Keatings, David Dodds
PURPOSE: To investigate feasibility and safety of SABR in the management of prostate cancer while employing MR/CT fusion for delineation, fiducial markers seeds for positioning and Varian Rapidarc with FFF delivery. METHODS: Forty-one patients were treated for low-intermediate risk prostate cancer with initial PSA (iPSA) of ≤20ng/ml, Gleason score 6-7. Patients had MR/CT fusion for delineation of prostate +/-seminal vesicles. CT/MR fusion images were used for delineation and planned using flattening filter free modality...
January 17, 2018: British Journal of Radiology
https://www.readbyqxmd.com/read/29337395/testosterone-suppression-with-luteinizing-hormone-releasing-hormone-lhrh-agonists-in-patients-receiving-radiotherapy-for-prostate-cancer
#18
Derek Wilke, Nikhilesh Patil, Helmut Hollenhorst, David Bowes, Robert Rutledge, Casely Ago
OBJECTIVES: To characterize the probability of testosterone escape during a course of radiotherapy and androgen deprivation (ADT) in patients with prostate cancer, and examine predictors of testosterone escape, the prostate specific antigen (PSA) levels during testosterone escape, and the impact of testosterone escape on outcome. PATIENTS AND METHODS: To participate in the database review, necessary data included: (i) type of luteinizing hormone-releasing hormone agonist (LHRHa) administered, date of initiation, and date of cessation or duration of therapy, (ii) radiotherapy information (start date and dose) with at least 6 months of follow-up after radiotherapy, (iii) had to have radiotherapy to the prostate or prostate bed, and (iv) had to have a least one serum testosterone and PSA measurement...
January 16, 2018: Pharmacotherapy
https://www.readbyqxmd.com/read/29335350/epidemiology-and-medication-pattern-change-of-psoriatic-diseases-in-taiwan-from-2000-to-2013-a-nationwide-population-based-cohort-study
#19
James Cheng-Chung Wei, Lin-Hong Shi, Jing-Yang Huang, Xue-Fen Wu, Rui Wu, Jeng-Yuan Chiou
OBJECTIVE: To analyze the trend of prevalence and incidence rates for psoriatic arthritis (PsA) and psoriasis in Taiwan, and to determine the changes in medication patterns. METHODS: Data were collected from the Taiwan National Health Insurance Research Database, which covered at least 95% of the population from 2000 to 2013. International Classification of Diseases, 9th edition (ICD-9) was used to identify PsA (ICD-9 696.0) and other psoriasis (ICD-9 696.1). Medications were identified by Anatomical Therapeutic Chemical Classification code...
January 15, 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/29334610/phase-ii-study-of-dovitinib-in-patients-with-castration-resistant-prostate-cancer-kcsg-gu11-05
#20
Yoon Ji Choi, Hye Sook Kim, Se Hoon Park, Bong-Seog Kim, Kyoung Ha Kim, Hyo Jin Lee, Hong Suk Song, Dong-Yeop Shin, Ha Young Lee, Hoon-Gu Kim, Kyung Hee Lee, Jae Lyun Lee, Kyong Hwa Park
Purpose: Fibroblast growth factor (FGF) signals are important in carcinogenesis and progression of prostate cancer. Dovitinib is an oral, pan-class inhibitor of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor, and fibroblast growth factor receptor (FGFR). We evaluated the efficacy and toxicity of dovitinib in men with metastatic castration resistant prostate cancer (mCRPC). Materials and Methods: This study was a single-arm, phase II, open-label, multicenter trial of dovitinib 500mg/day (5-days-on/2-days-off schedule)...
January 2, 2018: Cancer Research and Treatment: Official Journal of Korean Cancer Association
keyword
keyword
5863
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"